Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Netrin-1 (NTN1) signaling through DCC and UNC5H dependence receptors can inhibit apoptosis in human cancers, promoting tumor progression.
• Conversely, some cancers suppress apoptosis by silencing pro-apoptotic effector proteins.
• DAPK1 is a serine threonine kinase crucial for the netrin-1 dependence receptor-mediated pro-apoptotic pathway.

Purpose of the Study:

• To investigate the simultaneous loss of NTN1 and DAPK1 expression in human breast tumors.
• To explore the potential of DNA methylation inhibition to restore NTN1 and DAPK1 expression.
• To evaluate combination therapies involving DNA methylation inhibitors and netrin-1 targeting agents for cancer treatment.

Main Methods:

• Analysis of DNA methylation and gene expression in human breast tumors.
• Treatment of cancer cells with decitabine, a DNA methylation inhibitor.
• Assessment of NTN1 and DAPK1 expression restoration.
• In vivo studies using animal models to evaluate combination therapies.

Main Results:

• A significant proportion of human breast tumors showed concurrent, DNA methylation-dependent loss of NTN1 and DAPK1 expression.
• Decitabine treatment restored NTN1 and DAPK1 expression in cancer cells with low netrin-1 levels.
• Combining decitabine with NTN1 silencing or anti-netrin-1 antibodies enhanced tumor cell death and inhibited tumor growth in animal models.

Conclusions:

• Simultaneous epigenetic silencing of NTN1 and DAPK1 is a mechanism contributing to tumor progression in a subset of human breast cancers.
• DNA methylation inhibitors can reverse this silencing, restoring pro-apoptotic signaling.
• Combination therapy with DNA methylation inhibitors and netrin-1 neutralizing agents presents a promising strategy for cancer treatment.